CMS not convinced by BioZ data
This article was originally published in The Gray Sheet
Executive Summary
CMS Nov. 20 finalizes its proposed decision not to expand national coverage of CardioDynamics' BioZ transthoracic electrical bioimpedance test to guide treatment of drug-resistant hypertension. "The absence of a direct link from the intervention to the reported outcome is at the core of our reservations about the CONTROL trial," upon which the firm based its request, CMS writes. The agency provides guidelines as to what a more convincing trial might look like, including longer follow-up and tighter protocols. CardioDynamics says it will develop another hypertension study (1"The Gray Sheet" Sept. 4, 2006, p. 17)...
You may also be interested in...
BioZ gains local coverage
CardioDynamics snags expanded coverage of its BioZ impedance cardiography (ICG) technology with policy reversals from two local Medicare contractors, the firm announces Aug. 7. The contractors for patients in Mississippi, Alabama, Georgia and South Carolina will now cover the noninvasive test to guide treatment of high blood pressure. CMS denied national coverage of the hypertension indication in a November 2006 decision, but left discretion up to local carriers (1"The Gray Sheet" Nov. 27, 2006, In Brief). According to CEO Michael Perry, the firm has "begun to experience a recovery in its ICG business" during the past two quarters...
BioZ Coverage Expansion Effort Requires Another Study, Firm Says
CardioDynamics will develop an additional trial of its BioZ impedance cardiography (ICG) test for managing drug-resistant hypertension patients following CMS' proposed rejection of expanded Medicare coverage for the procedure
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.